N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Test was conducted according to EU Method B.6 and compliant with GLP.

Data source

Reference

Reference Type:

other: Body responsible for the test

Title:

Unnamed

Year:

1987

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

EU Method B.6 (Skin Sensitisation)

Deviations:

not specified

GLP compliance:

yes

Type of study:

other: maximization test according to Magnusson and Kligman

Test material

Test material information

Constituent 1

Reference substance name:

1,3,5-Triazine-2,4,6-triamine, N2,N2'-1,2-ethanediylbis[N2-[3-[[4,6-bis[butyl(1,2,2,6,6- pentamethyl-4-piperidinyl)amino]-1,3,5-triazin-2-yl]amino]propyl]-N4,N6-dibutyl-N4,N6-bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-

IUPAC Name:

1,3,5-Triazine-2,4,6-triamine, N2,N2'-1,2-ethanediylbis[N2-[3-[[4,6-bis[butyl(1,2,2,6,6- pentamethyl-4-piperidinyl)amino]-1,3,5-triazin-2-yl]amino]propyl]-N4,N6-dibutyl-N4,N6-bis(1,2,2,6,6-pentamethyl-4-piperidinyl)-

Constituent 2

Reference substance name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

EC Number:

401-990-0

EC Name:

N,N',N'',N'''-tetrakis(4,6-bis(butyl-(N-methyl-2,2,6,6-tetramethylpiperidin-4-yl)amino)triazin-2-yl)-4,7-diazadecane-1,10-diamine

Cas Number:

106990-43-6

Molecular formula:

C132H250N32

IUPAC Name:

N2-[2-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}[3-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}amino)propyl]amino)ethyl]-N2-[3-({4,6-bis[butyl(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]-1,3,5-triazin-2-yl}amino)propyl]-N4,N6-dibutyl-N4,N6-bis(1,2,2,6,6-pentamethylpiperidin-4-yl)-1,3,5-triazine-2,4,6-triamine

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

In vivo test system

Test animals

Species:

guinea pig

Strain:

other: Pirbright white strain DHP

Sex:

not specified

Study design: in vivo (non-LLNA)

Induction

Induction 1

Route:

intradermal and epicutaneous

Vehicle:

other: vaseline

Induction 2

Concentration / amount:

Concentration of test material and vehicle used at induction:
First induction (intradermal injection): 1% in sesame oil and adjuvant saline mixture.
Second induction (epidermal application): 10% in vaseline
Concentration of test material and vehicle used for each challenge:
0.3% in vaseline

Challenge

Concentration / amount:

Concentration of test material and vehicle used at induction:
First induction (intradermal injection): 1% in sesame oil and adjuvant saline mixture.
Second induction (epidermal application): 10% in vaseline
Concentration of test material and vehicle used for each challenge:
0.3% in vaseline

No. of animals per dose:

Number of animals in test group: 20
Number of animals in negative control group: 10

Results and discussion

In vivo (non-LLNA)

Results

Reading:

other: n/a

Group:

test chemical

Dose level:

0.3%

No. with + reactions:

10

Total no. in group:

20

Remarks on result:

other: Reading: other: n/a. Group: test group. Dose level: 0.3%. No with. + reactions: 10.0. Total no. in groups: 20.0.

Any other information on results incl. tables

Evidence of sensitisation of each challenge concentration: 60 -75% of the animals were sensitized under the experimental conditions employed.

Data imcomplete

Applicant's summary and conclusion

Interpretation of results:

other: Irritant

Remarks:

Criteria used for interpretation of results: EU

Conclusions:

the substance is classified as a skin sensitizer.